A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Press release
Astellas received the Notice from AstraZeneca Not to Exercise the Option to Acquire Diabetes Assets from Prosidion, a Subsidiary of Astellas
Nov 15, 2012

Tokyo, 15 November, 2012 –Astellas Pharma Inc. (Tokyo: 4503, ”Astellas”) announced today that it received a notice from AstraZeneca not to exercise an exclusive option to acquire the Phase II clinical and pre-clinical assets, PSN821 and PSN842 respectively, for the treatment of type 2 diabetes.

AstraZeneca and Prosidion Limited, a fully-owned subsidiary of Astellas, and Astellas have entered into an option agreement in December 2011, under which Prosidion granted to AstraZeneca the exclusive option to acquire these assets.

Astellas does not plan to make further development of PSN821 and PSN842.

 
Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: ＋81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)
1 /